Overview |
bs-0279R-Cy3 |
VEGF Polyclonal Antibody, Cy3 Conjugated |
WB, FCM, IF(IHC-P), IF(IHC-F) |
Human, Mouse, Rat, Pig, Goat, Others |
Specifications |
Cy3 |
Rabbit |
KLH conjugated synthetic peptide derived from human VEGF |
27-120/232 |
Polyclonal |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
Target |
7422 |
P15692 |
Secreted |
VPF; VEGF; MVCD1; Vascular endothelial growth factor A; VEGF-A; Vascular permeability factor; VEGFA |
Growth factor active in angiogenesis, vasculogenesis and endothelial cell growth. Induces endothelial cell proliferation, promotes cell migration, inhibits apoptosis and induces permeabilization of blood vessels. Binds to the FLT1/VEGFR1 and KDR/VEGFR2 receptors, heparan sulfate and heparin. NRP1/Neuropilin-1 binds isoforms VEGF-165 and VEGF-145. Isoform VEGF165B binds to KDR but does not activate downstream signaling pathways, does not activate angiogenesis and inhibits tumor growth. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IF(IHC-P) |
1:50-200 |
IF(IHC-F) |
1:50-200 |